Cisplatin Treatment Options

A collection of 1426 research studies where Cisplatin is the interventional treatment. These studies are located in the United States. Cisplatin is used for conditions such as Head and Neck Cancer, Lung Cancer and Non-small Cell Lung Cancer.

Home

All Treatments

Cisplatin

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

NCT04025879

Active Not Recruiting

The main purpose of the study is to examine if periadjuvant (neoadjuvant, then adjuvant) immunotherapy will prolong event free survival in participants with early stage non-small cell lung cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/26/2024

Locations: Local Institution - 0104, Tampa, Florida +107 locations

Local Institution - 0104, Tampa, Florida

Local Institution - 0040, Atlanta, Georgia

Local Institution - 0120, Augusta, Georgia

Local Institution - 0145, Chicago, Illinois

Local Institution - 0078, Chicago, Illinois

Local Institution - 0121, Orland Park, Illinois

Rcca Md Llc, Bethesda, Maryland

Local Institution - 0074, Boston, Massachusetts

Local Institution - 0076, Boston, Massachusetts

Local Institution - 0086, Traverse City, Michigan

Local Institution - 0100, Lebanon, New Hampshire

Local Institution - 0055, Cincinnati, Ohio

Local Institution - 0102, Cleveland, Ohio

Local Institution - 0054, Houston, Texas

Local Institution - 0103, Fredericksburg, Virginia

Local Institution - 0032, Ciudad Autonoma Beunos Aires, Buenos Aires

Local Institution - 0031, ABB, Ciudad Autónoma De Buenos Aires

Local Institution - 0043, Buenos Aires, Not set

Local Institution - 0030, Caba, Not set

Local Institution - 0020, Sydney, New South Wales

Local Institution - 0033, Heidelberg, Victoria

Local Institution - 0122, Melbourne, Victoria

Local Institution - 0023, North Ballarat, Victoria

Local Institution - 0002, Edegem, Not set

Local Institution - 0005, Liege, Not set

Local Institution - 0001, Roeselare, Not set

Local Institution - 0035, Belo Horizonte, Minas Gerais

Local Institution - 0029, Ijui, RIO Grande DO SUL

Local Institution - 0034, São Paulo, SAO Paulo

Local Institution - 0036, Sao Paulo, São Paulo

Local Institution - 0106, São Paulo, Not set

Local Institution - 0062, Oshawa, Ontario

Local Institution - 0115, Beijing, Beijing

Local Institution - 0096, Beijing, BEI

Local Institution - 0137, Fuzhou, Fujian

Local Institution - 0136, Fuzhou, Fujian

Local Institution - 0151, Hubei Sheng, Hubei

Local Institution - 0092, Changsha, Hunan

Local Institution - 0093, Changsha, Hunan

Local Institution - 0091, Changsha, Hunan

Local Institution - 0098, Shanghai, Shanghai

Local Institution - 0165, Shanghai, Shanghai

Local Institution - 0113, Shanghai, Shanghai

Local Institution - 0088, Chengdu, Sichuan

Local Institution - 0099, Hangzhou, Zhejiang

Local Institution - 0095, Shanghai, Not set

Local Institution - 0041, Praha 2, Not set

Local Institution - 0042, Praha 4, Not set

Local Institution - 0073, Besancon, Not set

Local Institution - 0037, La Tronche, Not set

Local Institution - 0050, Montpellier, Not set

Local Institution - 0038, Paris Cedex 18, Not set

Local Institution - 0051, Paris Cedex 20, Not set

Local Institution - 0083, Rennes Cedex 9, Not set

Local Institution - 0146, Rouen, Not set

Local Institution - 0110, Köln, Nordrhein-Westfalen

Local Institution - 0085, Berlin, Not set

Local Institution - 0065, Frankfurt, Not set

Local Institution - 0072, Georgsmarienhuette, Not set

Local Institution - 0071, Hamm, Not set

Local Institution - 0108, Heidelberg, Not set

Local Institution - 0109, Immenstadt, Not set

Local Institution - 0064, Loewenstein, Not set

Local Institution - 0147, Ludwigsburg, Not set

Local Institution - 0063, Luebeck, Not set

Local Institution - 0070, Moers, Not set

Local Institution - 0066, Muenchen, Not set

Local Institution - 0016, Dublin, Not set

Local Institution - 0024, Forlì, Not set

Local Institution - 0026, Milano, Not set

Azienda Ospedaliera Di Parma, Parma, Not set

Local Institution - 0135, Nagoya-shi, Aichi

Local Institution - 0124, Kashiwa-shi, Chiba

Local Institution - 0129, Kitakyushu-shi, Fukuoka

Local Institution - 0127, Kobe-shi, Hyogo

Local Institution - 0144, Kanazawa-shi, Ishikawa

Local Institution - 0125, Yokohama, Kanagawa

Local Institution - 0131, Sendai-shi, Miyagi

Local Institution - 0126, Sakai-shi, Osaka

Local Institution - 0130, Kitaadachigun, Saitama

Local Institution - 0142, Bunkyo-ku, Tokyo

Local Institution - 0133, Bunkyo-ku, Tokyo

Local Institution - 0143, Chuo-ku, Tokyo

Local Institution - 0134, Chuo-ku, Tokyo

Local Institution - 0132, Fukushima-shi, Not set

Local Institution - 0128, Hiroshima, Not set

Local Institution - 0077, Guadalajara, Jalisco

Local Institution - 0027, Monterrey, Nuevo Leon

Local Institution - 0028, Chihuahua, Not set

Local Institution - 0004, Groningen, Not set

Local Institution - 0003, Rotterdam, Not set

Local Institution - 0049, Kraków, Małopolskie

Local Institution - 0117, Hato Rey, Not set

Local Institution - 0013, Cluj-Napoca, Cluj

Local Institution - 0011, Bucuresti, Not set

Local Institution - 0012, Floresti, Not set

Local Institution, Moscow, Not set

Local Institution, Saint-Petersburg, Not set

Local Institution, St. Petersburg, Not set

Local Institution - 0046, Madrid, Not set

Local Institution - 0044, Majadahonda - Madrid, Not set

Local Institution - 0045, Valencia, Not set

Local Institution - 0149, Kaohsiung City, Not set

Local Institution - 0119, Kaohsiung, Not set

Local Institution - 0116, New Taipei City, Not set

Local Institution - 0112, Taipei City, Not set

Local Institution - 0007, Taunton, Not set

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin

NCT04541355

Completed

This phase II trial investigates how well sodium thiosulfate works in preventing ototoxicity (hearing loss/damage) in patients with squamous cell cancer of the head and neck that has spread to nearby tissue or lymph nodes (locally advanced) who are undergoing a chemoradiation. Sodium thiosulfate is a type of medication used to treat cyanide poisoning and to help lessen the side effects from cisplatin. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/25/2024

Locations: University of California, San Francisco, San Francisco, California

Conditions: Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVC Hypopharyngeal Carcinoma AJCC v8, Stage IVC Laryngeal Cancer AJCC v8, Stage IVC Lip and Oral Cavity Cancer AJCC v8, Stage IVC Oropharyngeal (p16-Negative) Carcinoma AJCC v8

Learn More ›

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

NCT04383743

Active Not Recruiting

This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as methotrexate, vinblastine, adriamycin, and cisplatin work in d... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/25/2024

Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

Conditions: Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma

Learn More ›

A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma

NCT04162015

Active Not Recruiting

This study will test whether giving nivolumab in combination with pemetrexed and either cisplatin or carboplatin before surgery is a safe and effective approach to treating resectable mesothelioma without delaying surgery.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/24/2024

Locations: Memoiral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations

Conditions: Malignant Pleural Mesothelioma

Learn More ›

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633

Recruiting

This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/18/2024

Locations: GSK Investigational Site, Goodyear, Arizona +95 locations

GSK Investigational Site, Goodyear, Arizona

GSK Investigational Site, Scottsdale, Arizona

GSK Investigational Site, Tucson, Arizona

GSK Investigational Site, Encinitas, California

GSK Investigational Site, Fountain Valley, California

GSK Investigational Site, Los Angeles, California

GSK Investigational Site, Whittier, California

GSK Investigational Site, Aurora, Colorado

GSK Investigational Site, Denver, Colorado

GSK Investigational Site, New Haven, Connecticut

GSK Investigational Site, Washington, District of Columbia

GSK Investigational Site, Jacksonville, Florida

GSK Investigational Site, Miami Beach, Florida

GSK Investigational Site, Sarasota, Florida

GSK Investigational Site, Tampa, Florida

GSK Investigational Site, Atlanta, Georgia

GSK Investigational Site, Augusta, Georgia

GSK Investigational Site, Arlington Heights, Illinois

GSK Investigational Site, Chicago, Illinois

GSK Investigational Site, Niles, Illinois

GSK Investigational Site, Iowa City, Iowa

GSK Investigational Site, Wichita, Kansas

GSK Investigational Site, Louisville, Kentucky

GSK Investigational Site, Pikeville, Kentucky

GSK Investigational Site, Rockville, Maryland

GSK Investigational Site, Boston, Massachusetts

GSK Investigational Site, Detroit, Michigan

GSK Investigational Site, Rochester, Minnesota

GSK Investigational Site, Saint Louis, Missouri

GSK Investigational Site, Hackensack, New Jersey

GSK Investigational Site, Bronx, New York

GSK Investigational Site, New York, New York

GSK Investigational Site, Cincinnati, Ohio

GSK Investigational Site, Cleveland, Ohio

GSK Investigational Site, Toledo, Ohio

GSK Investigational Site, Eugene, Oregon

GSK Investigational Site, Portland, Oregon

GSK Investigational Site, Bethlehem, Pennsylvania

GSK Investigational Site, Pittsburgh, Pennsylvania

GSK Investigational Site, Charleston, South Carolina

GSK Investigational Site, Greenville, South Carolina

GSK Investigational Site, Nashville, Tennessee

GSK Investigational Site, Austin, Texas

GSK Investigational Site, Dallas, Texas

GSK Investigational Site, Fort Worth, Texas

GSK Investigational Site, Houston, Texas

GSK Investigational Site, Longview, Texas

GSK Investigational Site, McAllen, Texas

GSK Investigational Site, San Antonio, Texas

GSK Investigational Site, San Marcos, Texas

GSK Investigational Site, Temple, Texas

GSK Investigational Site, Tyler, Texas

GSK Investigational Site, Weslaco, Texas

GSK Investigational Site, Fairfax, Virginia

GSK Investigational Site, Kennewick, Washington

GSK Investigational Site, Puyallup, Washington

GSK Investigational Site, Seattle, Washington

GSK Investigational Site, Tacoma, Washington

GSK Investigational Site, Madison, Wisconsin

GSK Investigational Site, Busan, Not set

GSK Investigational Site, Daegu, Not set

GSK Investigational Site, Seongnam-si, Gyeonggi-do, Not set

GSK Investigational Site, Seoul, Not set

GSK Investigational Site, Palma de Mallorca, Islas Baleares

GSK Investigational Site, Madrid, Navarra

GSK Investigational Site, Barcelona, Not set

GSK Investigational Site, Girona, Not set

GSK Investigational Site, Jerez de la Frontera, Not set

GSK Investigational Site, L'Hospitalet De Llobregat, Not set

GSK Investigational Site, Las Palmas De Gran Canaria, Not set

GSK Investigational Site, Madrid, Not set

GSK Investigational Site, Majadahonda (Madrid), Not set

GSK Investigational Site, Málaga, Not set

GSK Investigational Site, Pamplona, Not set

GSK Investigational Site, Santander, Not set

GSK Investigational Site, Sevilla, Not set

GSK Investigational Site, Valencia, Not set

GSK Investigational Site, Zaragoza, Not set

GSK Investigational Site, Taichung, Not set

GSK Investigational Site, Tainan City, Not set

GSK Investigational Site, Tainan, Not set

Conditions: Neoplasms

Learn More ›

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

NCT03138720

Active Not Recruiting

The purpose of this study is to determine if the combination of paclitaxel protein bound, gemcitabine, cisplatin, paricalcitol are effective in individuals with resectable and unresectable pancreatic cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/14/2024

Locations: HonorHealth Research Institute, Scottsdale, Arizona

Conditions: Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer

Learn More ›

Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)

NCT03635567

Completed

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) plus one of four platinum-based chemotherapy regimens compared to the efficacy and safety of placebo plus one of four platinum-based chemotherapy regimens in the treatment of adult women with persistent, recurrent, or metastatic cervical cancer. Possible chemotherapy regimens include: paclitaxel plus cisplatin with or without bevacizumab and paclitaxel plus carboplatin with or without bevacizumab. The prim... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/12/2024

Locations: Alaska Women's Cancer Care ( Site 1770), Anchorage, Alaska +148 locations

Alaska Women's Cancer Care ( Site 1770), Anchorage, Alaska

Arizona Oncology Associates, PC- HAL ( Site 8005), Phoenix, Arizona

UC Irvine Health ( Site 1796), Orange, California

Smilow Cancer Hospital at Yale New Haven ( Site 1809), New Haven, Connecticut

H. Lee Moffitt Cancer Center and Research Institute ( Site 1754), Tampa, Florida

Georgia Cancer Center at Augusta University ( Site 1767), Augusta, Georgia

Barbara Ann Karmanos Cancer Institute ( Site 1785), Detroit, Michigan

Henry Ford Health System ( Site 1810), Detroit, Michigan

Washington University School of Medicine ( Site 1779), Saint Louis, Missouri

Cancer Institute of New Jersey at University Hospital ( Site 1762), Newark, New Jersey

Holy Name Medical Center ( Site 1776), Teaneck, New Jersey

Mount Sinai Chelsea ( Site 1760), New York, New York

Columbia University Medical Center ( Site 1800), New York, New York

OSU Wexner Medical Center ( Site 1817), Hilliard, Ohio

University of Oklahoma- Stephenson Oklahoma Cancer Center ( Site 1784), Oklahoma City, Oklahoma

Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1768), Tulsa, Oklahoma

MUSC Hollings Cancer Center ( Site 1819), Charleston, South Carolina

West Cancer Center - East Campus ( Site 1763), Germantown, Tennessee

Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio, Texas

Seattle Cancer Care Alliance ( Site 1777), Seattle, Washington

Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1006), Berazategui, Buenos Aires

Hospital Aleman ( Site 1005), Buenos Aires, Not set

Hospital de Oncologia Angel Roffo ( Site 1003), Buenos Aires, Not set

Instituto Medico Especializado Alexander Fleming ( Site 1009), Buenos Aires, Not set

Centro Oncologico Riojano Integral ( Site 1004), La Rioja, Not set

Centro Medico San Roque ( Site 1001), Tucuman, Not set

Royal North Shore Hospital ( Site 1514), St Leonards, New South Wales

Mater Misericordiae Ltd Mater Cancer Care Centre ( Site 1521), South Brisbane, Queensland

Flinders Medical Centre ( Site 1513), Bedford Park, South Australia

St John of God Subiaco Hospital ( Site 1512), Subiaco, Western Australia

Monash Health-Monash Medical Centre ( Site 1519), Clayton, Not set

Tom Baker Cancer Centre ( Site 1728), Calgary, Alberta

BC Cancer-Kelowna - Sindi Ahluwalia Hawkins Centre ( Site 1734), Kelowna, British Columbia

BC Cancer - Vancouver Center ( Site 1722), Vancouver, British Columbia

CancerCare Manitoba ( Site 1725), Winnipeg, Manitoba

Queen Elizabeth II Health Sciences Centre ( Site 1731), Halifax, Nova Scotia

Juravinski Cancer Centre ( Site 1735), Hamilton, Ontario

London Regional Cancer Program - London HSC ( Site 1723), London, Ontario

The Ottawa Hospital Cancer Centre ( Site 1736), Ottawa, Ontario

Sunnybrook Research Institute ( Site 1733), Toronto, Ontario

Princess Margaret Cancer Centre ( Site 1732), Toronto, Ontario

CIUSSS du Saguenay-Lac-St-Jean ( Site 1729), Chicoutimi, Quebec

CIUSSS de l Est de L Ile de Montreal - Hopital Maisonneuve-Rosemont ( Site 1726), Montreal, Quebec

Centre Hospitalier de l Universite de Montreal - CHUM ( Site 1721), Montreal, Quebec

CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 1730), Sherbrooke, Quebec

CHU de Quebec-Universite Laval-Hotel Dieu de Quebec ( Site 1724), Quebec, Not set

Oncocentro ( Site 1065), Vina del Mar, Valparaiso

Fundacion Arturo Lopez Perez FALP ( Site 1061), Santiago, Not set

Sociedad Oncovida S.A. ( Site 1069), Santiago, Not set

Centro de Cancer Nuestra Senora de la Esperanza ( Site 1063), Santiago, Not set

Instituto Clinico Oncologico del Sur ( Site 1062), Temuco, Not set

Sociedad de Oncologia y Hematologia del Cesar Ltda. ( Site 1103), Valledupar, Cesar

Instituto Nacional de Cancerologia E.S.E ( Site 1095), Bogota, Cundinamarca

Hemato Oncologos S.A. ( Site 1100), Cali, Valle

Biomelab S A S ( Site 1104), Barranquilla, Not set

Oncomedica S.A. ( Site 1098), Monteria, Not set

Instituto Cancerologico de Narino Ltda ( Site 1097), Pasto, Not set

Centre Jean Perrin ( Site 1181), Clermont Ferrand, Not set

Institut Paoli Calmettes ( Site 1182), Marseille, Not set

Groupe Hospitalier Broca Cochin Hotel Dieu ( Site 1183), Paris, Not set

Centre Eugene Marquis ( Site 1187), Rennes, Not set

Institut Curie - Centre Rene Huguenin ( Site 1185), Saint-Cloud, Not set

Universitaetsklinikum Carl Gustav Carus ( Site 1211), Dresden, Not set

Universitaetsklinikum Duesseldorf ( Site 1220), Duesseldorf, Not set

Universitatsklinikum Essen AoR ( Site 1213), Essen, Not set

Universitatsklinikum Hamburg-Eppendorf ( Site 1212), Hamburg, Not set

Gynoncological Practice Lueck. Schrader. Noeding ( Site 1224), Hannover, Not set

Universitaetsklinikum Schleswig-Holstein Campus Kiel ( Site 1214), Kiel, Not set

Rotkreuzklinikum Muenchen gGmbH. Studienzentrale Frauenklinik ( Site 1225), Muenchen, Not set

Klinikum Oldenburg AoeR ( Site 1218), Oldenburg, Not set

Universitaet Regensburg ( Site 1221), Regensburg, Not set

Soroka Medical Center ( Site 1363), Beer-Sheva, Not set

Rambam Medical Center ( Site 1364), Haifa, Not set

Shaare Zedek Medical Center ( Site 1366), Jerusalem, Not set

Hadassah Medical Center. Ein Kerem ( Site 1367), Jerusalem, Not set

Rabin Medical Center ( Site 1365), Petah Tikva, Not set

Chaim Sheba Medical Center ( Site 1361), Ramat Gan, Not set

Sourasky Medical Center ( Site 1362), Tel Aviv, Not set

Centro di Riferimento Oncologico de Aviano Istituto Nazionale Tumori ( Site 1243), Aviano, Not set

A.O. Universitaria Policlinico S. Orsola-Malpighi ( Site 1245), Bolgna, Not set

Istituto Nazionale Tumori ( Site 1251), Milano, Not set

Istituto Europeo di Oncologia ( Site 1250), Milano, Not set

Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 1242), Napoli, Not set

Policlinico Universitario -Agostino Gemelli ( Site 1241), Roma, Not set

The Jikei University Kashiwa Hospital ( Site 1701), Kashiwa, Chiba

National Cancer Center Hospital East ( Site 1704), Kashiwa, Chiba

Ehime University Hospital ( Site 1693), Toon, Ehime

Kurume University Hospital ( Site 1692), Kurume, Fukuoka

National Hospital Organization Hokkaido Cancer Center ( Site 1700), Sapporo, Hokkaido

Hyogo Cancer Center ( Site 1705), Akashi, Hyogo

Iwate Medical University Hospital ( Site 1695), Shiwa-gun, Iwate

University of the Ryukyus Hospital ( Site 1706), Nakagami-gun, Okinawa

Saitama Medical University International Medical Center ( Site 1691), Hidaka, Saitama

Shizuoka Cancer Center Hospital and Research Institute ( Site 1703), Sunto-gun, Shizuoka

National Cancer Center Hospital ( Site 1702), Tokyo, Not set

The Jikei University Hospital ( Site 1697), Tokyo, Not set

The Cancer Institute Hospital of JFCR ( Site 1698), Tokyo, Not set

Keio University Hospital ( Site 1699), Tokyo, Not set

Keimyung University Dongsan Medical Center ( Site 1603), Daegu, Not set

Seoul National University Hospital ( Site 1602), Seoul, Not set

Asan Medical Center ( Site 1601), Seoul, Not set

Samsung Medical Center ( Site 1604), Seoul, Not set

Medical Care and Research S.A. de C.V. ( Site 1135), Merida, Yucatan

Centro Estatal de Cancerologia de Chihuahua ( Site 1123), Chihuahua, Not set

Consultorio de Medicina Especializada del Sector Privado ( Site 1129), Ciudad de Mexico, Not set

CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 1127), Ciudad de Mexico, Not set

Instituto Nacional de Cancerologia. ( Site 1130), Mexico, Not set

Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 1125), San Pedro Garza Garcia, Not set

Faicic S de RL de CV ( Site 1133), Veracruz, Not set

Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 1152), Trujillo, La Libertad

Centro Medico Monte Carmelo ( Site 1156), Arequipa, Not set

Hospital Nacional Guillermo Almenara Irigoyen ( Site 1158), Lima, Not set

Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 1157), Lima, Not set

Instituto Nacional de Enfermedades Neoplasicas ( Site 1153), Lima, Not set

Hospital Nacional Arzobispo Loayza ( Site 1159), Lima, Not set

Hospital Nacional Maria Auxiliadora ( Site 1155), Lima, Not set

Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1331), Kazan, Not set

FSBI National Medical Oncology Research Center n.a. N.N. Blokhina ( Site 1334), Moscow, Not set

Medical Rehabilitation Center ( Site 1337), Moscow, Not set

Novosibirsk Regional Clinical Oncology Dispensary ( Site 1358), Novosibirsk, Not set

Municipal Clinical Oncology Center ( Site 1346), Saint Petersburg, Not set

National Research Ogarev Mordovia State University ( Site 1347), Saransk, Not set

National Medical Research Center of Oncology n.a. N. N. Petrov ( Site 1348), St. Petersburg, Not set

Tomsk Scientific Research Institute of Oncology ( Site 1360), Tomsk, Not set

Republican Clinical Oncology Dispensary of Republic of Bashkortostan ( Site 1345), Ufa, Not set

Onkologikoa - Instituto Oncologico de San Sebastian ( Site 1275), Doniostia - San Sebastian, Guipuzcoa

Hospital Quiron Madrid ( Site 1277), Pozuelo de Alarcon, Madrid

Hospital Germans Trias i Pujol. ICO de Badalona ( Site 1276), Badalona, Not set

MD Anderson Cancer Center Madrid ( Site 1273), Madrid, Not set

Hospital Universitario Virgen Macarena ( Site 1274), Sevilla, Not set

Kaohsiung Veterans General Hospital ( Site 1632), Kaohsiung, Not set

China Medical University Hospital ( Site 1635), Taichung, Not set

Taichung Veterans General Hospital ( Site 1634), Taichung, Not set

Koo Foundation Sun Yat-Sen Cancer Center ( Site 1636), Taipei, Not set

Taipei Veterans General Hospital ( Site 1631), Taipei, Not set

Chang Gung Medical Foundation. Linkou ( Site 1633), Taoyuan, Not set

Baskent Adana Dr Turgut Noyan Uygulama ve Arastirma Merkezi ( Site 1457), Adana, Not set

Hacettepe University Medical Faculty ( Site 1459), Ankara, Not set

Baskent Universitesi Ankara Hastanesi ( Site 1451), Ankara, Not set

Akdeniz Universitesi Tip Fakultesi ( Site 1453), Antalya, Not set

Medeniyet University Goztepe Egitim ve Arastırma Hast. Merdivenkoy ( Site 1458), Istanbul, Not set

Ege University Medical Faculty Tulay Aktas Oncology Hospital ( Site 1456), Izmir, Not set

Necmettin Erbakan Universitesi Meram Tip Fakultesi Hastanesi ( Site 1452), Konya, Not set

City Clinical Hosp.4 of DCC ( Site 1482), Dnipropetrovsk, Not set

MI Precarpathian Clinical Oncology Center ( Site 1487), Ivano-Frankivsk, Not set

Communal non profit enterprise Regional Clinical Oncology Center ( Site 1489), Kharkiv, Not set

National Cancer Institute of the MoH of Ukraine ( Site 1484), Kyiv, Not set

MI Odessa Regional Oncological Centre ( Site 1493), Odesa, Not set

Medical Centre LLC Oncolife ( Site 1485), Zaporizhzhya, Not set

Conditions: Cervical Cancer

Learn More ›

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

NCT04677504

Completed

This study will evaluate the efficacy and safety of atezolizumab with bevacizumab in combination with cisplatin and gemcitabine(CisGem), compared with atezolizumab in combination with CisGem, in participants with advanced biliary tract cancer (BTC) who have not received prior systemic therapy. Treatment will consist of a chemotherapy combination phase followed by a cancer immunotherapy (CIT)/placebo phase.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/11/2024

Locations: City of Hope Cancer Center, Duarte, California +48 locations

City of Hope Cancer Center, Duarte, California

Massachusetts General Hospital, Boston, Massachusetts

Duke Cancer Center, Durham, North Carolina

Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee

University of Virginia, Charlottesville, Virginia

Nanfang Hospital, Southern Medical University, Guangzhou, Not set

Sir Run Run Shaw Hospital Zhejiang University, Hangzhou City, Not set

Zhongshan Hospital Fudan University, Shanghai, Not set

Queen Mary Hospital; Dept. Of Haematology & Oncology, Hong Kong, Not set

Prince of Wales Hosp; Dept. Of Clinical Onc, Shatin, Not set

Fondazione Pascale; U.O. Sperimentazioni Cliniche, Napoli, Campania

Azienda Ospedaliero Universitaria di Bologna; Istituto di Ematologia "Lorenzo e Ariosto Seragnoli", Bologna, Emilia-Romagna

Istituto Clinico Humanitas - Humanitas Cancer Center, Rozzano, Sicilia

IOV - Istituto Oncologico Veneto - IRCCS; Oncologia Medica II, Padova, Veneto

CHA Bundang Medical Center, Gyeonggi-do, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

SP ZOZ Wojewódzki Szpital Specjalistyczny nr 4; Oddzial Onkologii Klinicznej, Bytom, Not set

Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdansk, Not set

Szpital Wojewódzki im. Miko?aja Kopernika; Oddzia? Dzienny Chemioterapii, Koszalin, Not set

NIO im Marii Sklodowskiej-Curie; Klinika Onkologii i Radioterapii, Warszawa, Not set

Dolno?l?skie Centrum Onkologii; Oddzia? Onkologii Klinicznej i Chemioterapii, Wroc?aw, Not set

FSBI "National Medical Research Center of Oncology N.N. Blokhin?, Moscow, Moskovskaja Oblast

First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Moskovskaja Oblast

SBIH "Moscow Clinical Scientific and Practical Center named after A.S. Loginov of DHM", Moskva, Moskovskaja Oblast

GBUZ Saint Petersburg Clinical Research Center of Specialized Types of Care (Oncology), Saint Petersburg, Sankt Petersburg

Complejo Hospitalario de Navarra; Servicio de Oncologia, Pamplona, Navarra

Hospital Universitari Vall d'Hebron; Oncology, Barcelona, Not set

Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Not set

Complejo Hospitalario de Orense; Servicio de Oncologia, Orense, Not set

Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, Not set

Taipei Veterans General Hospital; Department of Oncology, Taipei City, Not set

National Taiwan Uni Hospital; Dept of Oncology, Taipei, Not set

Maharaj Nakorn Chiang Mai Hosp; Oncology Unit, Chiangmai, Not set

Srinagarind Hospital; Medical Oncology Unit, Khon Kaen, Not set

Sunpasitthiprasong Hospital; Oncology and/or Hematology, Ubon Ratchathani, Not set

Adana Ac?badem Hospital Oncology Department, Adana, Not set

Memorial Ankara Hastanesi, Ankara, Not set

Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department, Malatya, Not set

Koc Universitesi Hastanesi; T?bbi Onkoloji, Zeyt?nburnu, Not set

SI Institute of general&urgent surgery n/a Zaytseva V.T NAMSU, Kharkiv, Kharkiv Governorate

?Kharkov Regional Oncology Center, Kharkiv, Kharkiv Governorate

SI "Shalimov National Institute of Surgery and Transplantation" of Nat.Acad of Med.Sci of Ukraine, Kyiv, KIEV Governorate

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Royal Free Hospital, London, Not set

Churchill Hospital, Oxford, Not set

Royal Marsden Hospital (Sutton), Sutton, Not set

Conditions: Biliary Tract Cancer

Learn More ›

Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma

NCT05268614

Recruiting

This study builds on the results of several prior studies that we have been involved with to test the hypothesis that Risk-Adapted De-Intensification of Radiation Therapy and chemotherapy based on HPV subtype, plasma circulating free HPV DNA (cfHPV DNA) level, and cfHPV DNA clearance rate produces Local-Regional Control rates that are similar to what has been achieved with more aggressive therapy in patients with Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma (OPSCC).

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

06/11/2024

Locations: University of Florida, Gainesville, Florida +2 locations

Conditions: Oropharyngeal Squamous Cell Carcinoma

Learn More ›

Cisplatin in Castration Resistant Prostate Cancer

NCT03275857

Completed

It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/07/2024

Locations: Wilmot Cancer Institute, Rochester, New York

Conditions: Prostate Cancer

Learn More ›

Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

NCT05388773

Recruiting

This is a trial studying patients with human papilloma virus (HPV) positive oropharyngeal cancer with tumors that can be removed via transoral surgery. Following surgery, patients will be classified as either low, intermediate, or high risk based on the characteristics of the tumors. Low risk patients (Arm S) will receive no further treatment after surgery. Intermediate risk patients (Arm RT) will be treated with Intensity Modulated Radiotherapy (IMRT) after surgery. High risk patients (Arm CRT)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/05/2024

Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Conditions: Oropharynx Cancer

Learn More ›

A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

NCT01326871

Completed

This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 in a biochemotherapy regimen either containing cisplatin and gemcitabine or containing gemcitabine alone in patients who have muscle invasive or metastatic urothelial cancer of bladder, renal pelvis, ureters and urethra. The purpose of this study is to evaluate the safety, determine the maximum tolerated dose (MTD) and the recommended dose (RD), and assess the anti-tumor response of ALT-8... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/05/2024

Locations: The University of Arizona Cancer Center, Tucson, Arizona +15 locations

Conditions: Transitional Cell Carcinoma of Bladder, Urethra Cancer, Ureter Cancer, Malignant Tumor of Renal Pelvis

Learn More ›

Browse by State

Cisplatin treatment options in Alabama

Cisplatin treatment options in Alaska

Cisplatin treatment options in Arizona

Cisplatin treatment options in Arkansas

Cisplatin treatment options in California

Cisplatin treatment options in Colorado

Cisplatin treatment options in Connecticut

Cisplatin treatment options in Delaware

Cisplatin treatment options in District of Columbia

Cisplatin treatment options in Florida

Cisplatin treatment options in Georgia

Cisplatin treatment options in Hawaii

Cisplatin treatment options in Idaho

Cisplatin treatment options in Illinois

Cisplatin treatment options in Indiana

Cisplatin treatment options in Iowa

Cisplatin treatment options in Kansas

Cisplatin treatment options in Kentucky

Cisplatin treatment options in Louisiana

Cisplatin treatment options in Maine

Cisplatin treatment options in Montana

Cisplatin treatment options in Nebraska

Cisplatin treatment options in Nevada

Cisplatin treatment options in New Hampshire

Cisplatin treatment options in New Jersey

Cisplatin treatment options in New Mexico

Cisplatin treatment options in New York

Cisplatin treatment options in North Carolina

Cisplatin treatment options in North Dakota

Cisplatin treatment options in Ohio

Cisplatin treatment options in Oklahoma

Cisplatin treatment options in Oregon

Cisplatin treatment options in Maryland

Cisplatin treatment options in Massachusetts

Cisplatin treatment options in Michigan

Cisplatin treatment options in Minnesota

Cisplatin treatment options in Mississippi

Cisplatin treatment options in Missouri

Cisplatin treatment options in Pennsylvania

Cisplatin treatment options in Rhode Island

Cisplatin treatment options in South Carolina

Cisplatin treatment options in South Dakota

Cisplatin treatment options in Tennessee

Cisplatin treatment options in Texas

Cisplatin treatment options in Utah

Cisplatin treatment options in Vermont

Cisplatin treatment options in Virginia

Cisplatin treatment options in Washington

Cisplatin treatment options in West Virginia

Cisplatin treatment options in Wisconsin

Cisplatin treatment options in Wyoming